BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy
· Delayed Price · Currency is EUR 54.06
0.00 (0.00%)
At close: May 7, 2025, 5:30 PM CET
BioMarin Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,950 | 2,854 | 2,419 | 2,096 | 1,846 | 1,860 | Upgrade
|
| Revenue Growth (YoY) | 19.36% | 17.97% | 15.42% | 13.53% | -0.76% | 9.18% | Upgrade
|
| Cost of Revenue | 560.36 | 580.24 | 532.06 | 503.02 | 1,099 | 1,152 | Upgrade
|
| Gross Profit | 2,390 | 2,274 | 1,887 | 1,593 | 746.97 | 708.07 | Upgrade
|
| Selling, General & Admin | 893.41 | 913.2 | 892.41 | 823.24 | 759.38 | 737.67 | Upgrade
|
| Research & Development | 747.18 | 747.18 | 746.77 | 649.61 | - | - | Upgrade
|
| Operating Expenses | 1,674 | 1,704 | 1,701 | 1,538 | 821.28 | 799.83 | Upgrade
|
| Operating Income | 715.47 | 570.04 | 185.77 | 54.68 | -74.32 | -91.76 | Upgrade
|
| Interest Expense | -11.98 | -12.67 | -17.34 | -15.97 | -15.34 | -29.31 | Upgrade
|
| Interest & Investment Income | 74.53 | 74.88 | 58.34 | 18.03 | 10.48 | 16.61 | Upgrade
|
| Currency Exchange Gain (Loss) | -8.6 | -8.6 | -27.7 | -11.4 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.71 | 3.93 | 2.09 | -2.06 | 11.85 | 6.59 | Upgrade
|
| EBT Excluding Unusual Items | 770.13 | 627.59 | 201.16 | 43.28 | -67.32 | -97.87 | Upgrade
|
| Merger & Restructuring Charges | -95.83 | -95.83 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -12.6 | - | - | 0.55 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 10 | - | 108 | - | 52.82 | Upgrade
|
| Other Unusual Items | - | - | - | -1.7 | -8.03 | -4.5 | Upgrade
|
| Pretax Income | 674.31 | 541.76 | 188.56 | 149.58 | -75.35 | -49 | Upgrade
|
| Income Tax Expense | 150.42 | 114.9 | 20.92 | 8.02 | -11.27 | -903.03 | Upgrade
|
| Net Income | 523.88 | 426.86 | 167.65 | 141.56 | -64.08 | 854.03 | Upgrade
|
| Net Income to Common | 523.88 | 426.86 | 167.65 | 141.56 | -64.08 | 854.03 | Upgrade
|
| Net Income Growth | 154.99% | 154.62% | 18.43% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 191 | 190 | 188 | 185 | 183 | 181 | Upgrade
|
| Shares Outstanding (Diluted) | 196 | 197 | 192 | 189 | 183 | 192 | Upgrade
|
| Shares Change (YoY) | 1.65% | 2.67% | 1.39% | 3.34% | -4.61% | 7.06% | Upgrade
|
| EPS (Basic) | 2.75 | 2.25 | 0.89 | 0.76 | -0.35 | 4.72 | Upgrade
|
| EPS (Diluted) | 2.71 | 2.21 | 0.87 | 0.75 | -0.35 | 4.50 | Upgrade
|
| EPS Growth | 152.82% | 153.71% | 16.00% | - | - | - | Upgrade
|
| Free Cash Flow | 624.18 | 487.42 | 62.57 | 54.94 | 208.96 | -28.95 | Upgrade
|
| Free Cash Flow Per Share | 3.18 | 2.48 | 0.33 | 0.29 | 1.14 | -0.15 | Upgrade
|
| Gross Margin | 81.01% | 79.67% | 78.01% | 76.00% | 40.46% | 38.06% | Upgrade
|
| Operating Margin | 24.25% | 19.97% | 7.68% | 2.61% | -4.03% | -4.93% | Upgrade
|
| Profit Margin | 17.76% | 14.96% | 6.93% | 6.75% | -3.47% | 45.90% | Upgrade
|
| Free Cash Flow Margin | 21.16% | 17.08% | 2.59% | 2.62% | 11.32% | -1.56% | Upgrade
|
| EBITDA | 806.62 | 666.47 | 290.16 | 156.65 | 33.72 | 13.41 | Upgrade
|
| EBITDA Margin | 27.34% | 23.35% | 11.99% | 7.47% | 1.83% | 0.72% | Upgrade
|
| D&A For EBITDA | 91.15 | 96.43 | 104.39 | 101.97 | 108.04 | 105.17 | Upgrade
|
| EBIT | 715.47 | 570.04 | 185.77 | 54.68 | -74.32 | -91.76 | Upgrade
|
| EBIT Margin | 24.25% | 19.97% | 7.68% | 2.61% | -4.03% | -4.93% | Upgrade
|
| Effective Tax Rate | 22.31% | 21.21% | 11.09% | 5.36% | - | - | Upgrade
|
| Revenue as Reported | 2,950 | 2,854 | 2,419 | 2,096 | 1,846 | 1,860 | Upgrade
|
| Advertising Expenses | - | 34.5 | 27.8 | 25.2 | 30.2 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.